(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.08%) $0.927
(0.25%) $10.87
(0.07%) $0.793
(-1.05%) $91.60
-1.22% SEK 113.40
Live Chart Being Loaded With Signals
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases...
Stats | |
---|---|
Today's Volume | 52 476.00 |
Average Volume | 245 585 |
Market Cap | 6.09B |
EPS | SEK0 ( 2024-02-20 ) |
Next earnings date | ( SEK-0.900 ) 2024-05-06 |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | -13.05 |
ATR14 | SEK0.133 (0.12%) |
Volume Correlation
Calliditas Therapeutics Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Calliditas Therapeutics Correlation - Currency/Commodity
Calliditas Therapeutics Financials
Annual | 2023 |
Revenue: | SEK1.21B |
Gross Profit: | SEK1.15B (94.99 %) |
EPS: | SEK-8.69 |
Q4 | 2023 |
Revenue: | SEK451.56M |
Gross Profit: | SEK429.26M (95.06 %) |
EPS: | SEK-0.340 |
Q3 | 2023 |
Revenue: | SEK294.59M |
Gross Profit: | SEK279.67M (94.94 %) |
EPS: | SEK-3.14 |
Q2 | 2023 |
Revenue: | SEK269.38M |
Gross Profit: | SEK255.17M (94.72 %) |
EPS: | SEK-1.710 |
Financial Reports:
No articles found.
Calliditas Therapeutics
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators